Latest Insights Into Marginal Zone Lymphoma Management and Treatment
At the 2026 Leukemia, Lymphoma & Myeloma Symposium (LL&M) Winter Symposium in Amelia Island, Florida, Jacqueline Barrientos, MD, MS, Mount Sinai Medical Center, Miami, Florida presented on new clinical insights in marginal zone lymphoma.
Transcript:
My name is Jacqueline Barrientos. I'm the chief of hematologic malignancies and director of oncological research at Mount Sinai Medical Center in Miami Beach. I am here at LL&M winter session in Amelia Island to discuss the treatment strategies for my management of marginal zone lymphoma as the field is evolving quite rapidly.
My talk was given an overview of the current treatment strategies for the different subtypes of marginal cell lymphoma, and we touch upon the novel agents in clinical development and including the recent approval by the FDA of CAR-T with lisocabtagene maraleucel (liso-cel.)
In addition to that, we discuss therapies with targeted agents in combination and other emerging therapies such as by specific antibodies that are currently commercial available for other types of lymphoma, but not yet for marginalized lymphoma.
I hope that you enjoy our talks.
Source:
Barrientos J. Marginal Zone Lymphoma: Advancing Toward 2026 with New Clinical Insights. Presented at Lymphoma, Leukemia & Myeloma Winter Symposium; January 30-February 1, 2026 Amelia Island, Fl.
